|
| Trial no. | Reference | NCT number | Drug | Treatment Regimens | Involving Patients | Rash | Previous therapy | Phase | Tumor Type |
|
| 1 | Borghaei H, et al. 2015 [22] | NCT01673867 (CheckMate 057) | Nivolumab (PD-1) | Nivolumab versus Docetaxel | 555 | 35 | Yes | III | Advanced non-squamous NSCLC |
| 2 | Weber JS, et al. 2015 [23] | NCT01721746 (CheckMate 037) | Nivolumab (PD-1) | Nivolumab versus Dacarbazine/Paclitaxel plus Carboplatin | 370 | 30 | No | III | Advanced melanoma |
| 3 | Brahmer J, et al. 2015 [24] | NCT01642004 (CheckMate 017) | Nivolumab (PD-1) | Nivolumab versus Docetaxel | 260 | 13 | Yes | III | Advanced squamous cell NSCLC |
| 4 | Motzer RJ, et al. 2015 [25] | NCT01668784 (CheckMate 025) | Nivolumab (PD-1) | Nivolumab versus Everolimus | 803 | 120 | Yes | III | Advanced RCC |
| 5 | Herbst RS, et al. 2016A [26] | NCT01905657 (KEYNOTE-010) | Pembrolizumab (PD-1) | Pembrolizumab 2 mg/kg versus Pembrolizumab 10 mg/kg | 991 | 73 | Yes | II/III | Advanced NSCLC |
| Herbst RS, et al. 2016B [26] | Pembrolizumab 2 mg/kg versus Docetaxel | 43 |
| Herbst RS, et al. 2016C [26] | Pembrolizumab 10 mg/kg versus Docetaxel | 58 |
| 6 | Langer CJ, et al. 2016 [27] | NCT02039674 (KEYNOTE-021) | Pembrolizumab (PD-1) | Pembrolizumab plus Carboplatin plus Pemetrexed versus Carboplatin plus Pemetrexed | 121 | 25 | No | II | Advanced nonsquamous NSCLC |
| Awad MM, et al. 2021 [28] |
| 7 | Antonia SJ, et al. 2016 [29] | NCT01928394 (CheckMate 032) | Nivolumab (PD-1) | Nivolumab versus Nivolumab plus Ipilimumab | 152 | 6 | Yes | I/II | Recurrent SCLC |
| 8 | Ferris RL, et al. 2016 [30] | NCT02105636 (CheckMate 141) | Nivolumab (PD-1) | Nivolumab versus (Methotrexate, Docetaxel, or Cetuximab) | 347 | 23 | Yes | III | Recurrent HNSCC |
| 9 | Hodi FS, et al. 2016 [31] | NCT01927419 (CheckMate 069) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Ipilimumab | 140 | 54 | No | II | Advanced melanoma |
| 10 | Bellmunt J, et al. 2017 [32] | NCT02256436 (KEYNOTE-045) | Pembrolizumab (PD-1) | Pembrolizumab versus Chemotherapy | 531 | 45 | Yes | III | Advanced UC |
| 11 | Kang YK, et al. 2017 [33] | NCT02267343 (ONO-4538-12, ATTRACTION-2) | Nivolumab (PD-1) | Nivolumab versus Placebo | 491 | 24 | Yes | III | Advanced gastric or GJC |
| 12 | Schachter J, et al. 2017A [34] | NCT01866319 (KEYNOTE-006) | Pembrolizumab (PD-1) | Pembrolizumab every 2 weeks versus Pembrolizumab every 3 weeks | 811 | 92 | Yes | III | Advanced melanoma |
| Schachter J, et al. 2017B [34] | Pembrolizumab every 2 weeks versus Ipilimumab | 84 |
| Schachter J, et al. 2017C [34] | Pembrolizumab every 3 weeks versus Ipilimumab | 88 |
| 13 | Antonia SJ, et al. 2017 [35] | NCT02125461 (PACIFIC) | Durvalumab (PD-L1) | Durvalumab versus Placebo | 709 | 50 | Yes | III | Advanced, unresectable, stage III NSCLC |
| 14 | Socinski MA, et al. 2018 [36] | NCT02366143 (IMpower150) | Atezolizumab (PD-L1) | Atezolizumab plus Bevacizumab plus Carboplatin plus Paclitaxel (ABCP) versus Bevacizumab plus Carboplatin plus Paclitaxel (BCP) | 787 | 72 | No | III | Metastatic nonsquamous NSCLC |
| 15 | Paz-Ares L, et al. 2018 [37] | NCT02775435 (KEYNOTE-407) | Pembrolizumab (PD-1) | Pembrolizumab plus chemotherapy versus chemotherapy | 558 | 79 | No | III | Squamous NSCLC |
| 16 | Horn L, et al. 2018 [38] | NCT02763579 (IMpower133) | Atezolizumab (PD-L1) | Atezolizumab plus Carboplatin plus Etoposide versus Carboplatin plus Etoposide | 394 | 57 | No | III | Extensive-stage SCLC |
| 17 | Antonia SJ, et al. 2018 [39] | NCT02125461 (PACIFIC) | Durvalumab (PD-L1) | Durvalumab versus Placebo | 709 | 76 | Yes | III | Stage III NSCLC |
| 18 | Gandhi L, et al. 2018 [40] | NCT02578680 (KEYNOTE-189) | Pembrolizumab (PD-1) | Pembrolizumab plus Pemetrexed plus A platinum-based drug versus Pemetrexed plus A platinum-based drug | 607 | 105 | No | II | Metastatic nonsquamous NSCLC |
| Gadgeel S, et al. 2020 [41] |
| Rodríguez-Abreu D, et al. 2021 [42] |
| 19 | Hida T, et al. 2018 [43] | NCT02008227 (OAK) | Atezolizumab (PD-L1) | Atezolizumab versus Docetaxel | 101 | 22 | Yes | III | Advanced/metastatic NSCLC |
| 20 | Eggermont AMM, et al. 2018 [44] | NCT02362594 | Pembrolizumab (PD-1) | Pembrolizumab versus Placebo | 1011 | 136 | No | III | Resected stage III melanoma |
| 21 | Schmid P, et al. 2018 [45] | NCT02425891 (IMpassion130) | Atezolizumab (PD-L1) | Atezolizumab plus Nab-paclitaxel versus Nab-paclitaxel | 890 | 113 | No | III | Unresectable locally advanced or metastatic TNBC |
| Emens LA, et al. 2021 [46] |
| 22 | Hellmann MD, et al. 2018A [47] | NCT02477826 (CheckMate 227) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Nivolumab | 1537 | 139 | No | III | Stage IV or recurrent NSCLC |
| Hellmann MD, et al. 2018B [47] | Nivolumab plus Ipilimumab versus Chemotherapy (platinum doublet) | 125 |
| Hellmann MD, et al. 2018C [47] | Nivolumab versus Chemotherapy (platinum doublet) | 72 |
| Reck M, et al. 2021A [48] | Nivolumab plus Ipilimumab versus Nivolumab | 139 |
| Reck M, et al. 2021B [48] | Nivolumab plus Ipilimumab versus Chemotherapy (platinum doublet) | 125 |
| Reck M, et al. 2021C [48] | Nivolumab versus Chemotherapy (platinum doublet) | 72 |
| 23 | Powles T, et al. 2018A [49] | NCT02302807 (IMvigor211) | Atezolizumab (PD-L1) | Atezolizumab versus Chemotherapy (vinflunine paclitaxel or docetaxel) | 1128 | 20 | YSE | III | Locally advanced or metastatic UC |
| Powles T, et al. 2018B [49] | Atezolizumab versus Chemotherapy (vinflunine paclitaxel or docetaxel) | 61 |
| 24 | Paz-Ares L, et al. 2019 [50] | NCT03043872 (CASPIAN) | Durvalumab (PD-L1) | Durvalumab plus EP versus EP | 531 | 6 | No | III | Extensive-stage SCLC |
| 25 | Motzer RJ, et al. 2019 [51] | NCT02684006 (JAVELIN Renal 101) | Avelumab (PD-L1) | Avelumab plus Axitinib versus Sunitinib | 873 | 96 | Yes | III | Advanced RCC |
| Motzer RJ, et al. 2020 [52] |
| 26 | West H, et al. 2019 [53] | NCT02367781 (IMpower130) | Atezolizumab (PD-L1) | Atezolizumab plus Carboplatin plus Nab-paclitaxel versus Carboplatin plus Nab-paclitaxel | 705 | 25 | No | III | Metastatic nonsquamous NSCLC |
| 27 | Kato K, et al. 2019 [54] | NCT02569242 (ATTRACTION-3) | Nivolumab (PD-1) | Nivolumab versus Paclitaxel/Docetaxel | 417 | 54 | Yes | III | Advanced OSCC |
| 28 | Motzer R, et al. 2019 [55] | NCT02231749 (CheckMate 214) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Sunitinib | 1082 | 193 | No | III | Advanced RCC |
| 29 | Rini BI, et al. 2019 [56] | NCT02420821 (IMmotion151) | Atezolizumab (PD-L1) | Atezolizumab plus Bevacizumab versus Sunitinib | 907 | 128 | No | III | Metastatic RCC |
| 30 | Sullivan RJ, et al. 2019 [57] | NCT01656642 | Atezolizumab (PD-L1) | Atezolizumab plus Vemurafenib versus Atezolizumab plus Cobimetinib plus Vemurafenib | 56 | 20 | No | Ib | BRAF-mutated melanoma |
| 31 | Hellmann MD, et al. 2019A [58] | NCT02477826 (CheckMate 227) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Nivolumab | 1537 | 139 | No | III | Advanced NSCLC |
| Hellmann MD, et al. 2019B [58] | Nivolumab plus Ipilimumab versus Chemotherapy (platinum doublet) | 125 |
| Hellmann MD, et al. 2019C [58] | Nivolumab versus Chemotherapy (platinum doublet) | 72 |
| 32 | Wu YL, et al. 2019 [59] | NCT02613507 (CheckMate 078) | Nivolumab (PD-1) | Nivolumab versus Docetaxel | 493 | 43 | Yes | III | Advanced NSCLC |
| 33 | Cohen EEW, et al. 2019 [60] | NCT02252042 (KEYNOTE-040) | Pembrolizumab (PD-1) | Pembrolizumab versus (Methotrexate, Docetaxel, or Cetuximab) | 480 | 53 | Yes | III | Recurrent or metastatic HNSCC |
| 34 | Mok TSK, et al. 2019 [61] | NCT02220894 (KEYNOTE-042) | Pembrolizumab (PD-1) | Pembrolizumab versus Chemotherapy | 1251 | 73 | No | III | Locally advanced or metastatic NSCLC |
| Wu YL, et al. 2021 [62] |
| 35 | Burtness B, et al. 2019A [63] | NCT02358031 (KEYNOTE-048) | Pembrolizumab (PD-1) | Pembrolizumab versus Pembrolizumab plus Chemotherapy | 863 | 59 | No | III | Recurrent or Metastatic HNSCC |
| Burtness B, et al. 2019B [63] | Pembrolizumab versus Cetuximab plus Chemotherapy | 141 |
| Burtness B, et al. 2019C [63] | Pembrolizumab plus Chemotherapy versus Cetuximab plus Chemotherapy | 140 |
| 36 | Finn RS, et al. 2020 [64] | NCT03434379 | Atezolizumab (PD-L1) | Atezolizumab plus Bevacizumab versus Sorafenib | 485 | 68 | No | III | Unresectable hepatocellular carcinoma |
| 37 | Gutzmer R, et al. 2020 [65] | NCT02908672 (IMspire150) | Atezolizumab (PD-L1) | Atezolizumab plus Vemurafenib plus Cobimetinib versus Vemurafenib plus Cobimetinib | 511 | 209 | No | III | Unresectable advanced BRAFV600 mutation-positive melanoma |
| 38 | Mittendorf EA, et al. 2020 [66] | NCT03197935 (IMpassion031) | Atezolizumab (PD-L1) | Atezolizumab + Chemotherapy versus Chemotherapy | 331 | 88 | No | III | Early stage TNBC |
| 39 | Ascierto PA, et al. 2020 [67] | NCT02388906 (CheckMate 238) | Nivolumab (PD-1) | Nivolumab versus Ipilimumab | 905 | 197 | No | III | Resected stage IIIB–C and stage IV Melanoma |
| 40 | Herbst RS, et al. 2020 [68] | NCT02409342 (IMpower110) | Atezolizumab (PD-L1) | Atezolizumab versus Chemotherapy (platinum-based) | 549 | 63 | No | III | PD-L1-selected NSCLC |
| 41 | Emens LA, et al. 2020 [69] | NCT02924883 (KATE2) | Atezolizumab (PD-L1) | Atezolizumab plus Trastuzumab emtansine versus Trastuzumab emtansine | 200 | 34 | Yes | II | HER2-positive advanced breast cancer |
| 42 | Huang J, et al. 2020 [70] | NCT03099382 (ESCORT) | Camrelizumab (PD-1) | Camrelizumab versus Chemotherapy (Docetaxel or Irinotecan) | 448 | 189 | Yes | III | Advanced or metastatic OSCC |
| 43 | Powles, et al. 2020 [71] | NCT02603432 (JAVELIN Bladder 100) | Avelumab (PD-L1) | Avelumab versus Best Supportive Care (BSC) | 689 | 44 | Yes | III | Advanced or metastatic UC |
| 44 | André T, et al. 2020 [72] | NCT02563002 (KEYNOTE-177) | Pembrolizumab (PD-1) | Pembrolizumab versus Chemotherapy (5-fluorouracil–based therapy with or without bevacizumab or cetuximab) | 296 | 36 | No | III | Colorectal cancer |
| 45 | Schmid P, et al. 2020 [73] | NCT03036488 (KEYNOTE-522) | Pembrolizumab (PD-1) | Pembrolizumab plus Chemotherapy (Paclitaxel plus Carboplatin) versus Placebo plus Chemotherapy (Paclitaxel plus Carboplatin) | 1170 | 229 | No | III | Stage II or stage III TNBC |
| 46 | Jotte R, et al. 2020 [74] | NCT02367794 (IMpower131) | Atezolizumab (PD-L1) | Atezolizumab plus Carboplatin plus Nab-paclitaxel versus Carboplatin plus Nab-paclitaxel | 668 | 38 | Yes | III | Advanced squamous NSCLC |
| 47 | Zhou C, et al. 2020 [75] | NCT03134872 (CameL) | Camrelizumab (PD-1) | Camrelizumab plus Carboplatin plus Pemetrexed versus Carboplatin plus Pemetrexed | 412 | 36 | No | III | Nonsquamous NSCLC |
| 48 | Zimmer L, et al. 2020A [76] | NCT02523313 (IMMUNED) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Nivolumab | 162 | 6 | Yes | II | Resected stage IV melanoma |
| Zimmer L, et al. 2020B [76] | Nivolumab plus Ipilimumab versus Placebo | N/A |
| Zimmer L, et al. 2020C [76] | Nivolumab versus Placebo | N/A |
| 49 | Galsky MD, et al. 2020A [77] | NCT02807636 (IMvigor130) | Atezolizumab (PD-L1) | Atezolizumab plus Chemotherapy (platinum-based) versus Atezolizumab | 1203 | 75 | No | III | Locally advanced or metastatic UC |
| Galsky MD, et al. 2020B [77] | Atezolizumab plus Chemotherapy versus Chemotherapy | 80 |
| Galsky MD, et al. 2020C [77] | Atezolizumab versus Placebo plus Chemotherapy | 41 |
| 50 | Powles T, et al. 2020A [78] | NCT02516241 (DANUBE) | Durvalumab (PD-L1) | Durvalumab versus Durvalumab plus Tremelimumab | 998 | 73 | No | III | Unresectable advanced or metastatic UC |
| Powles T, et al. 2020B [78] | Durvalumab versus Chemotherapy (gemcitabine plus cisplatin/carboplatin) | 34 |
| 51 | Rudin CM, et al. 2020 [79] | NCT03066778 (KEYNOTE-604) | Pembrolizumab (PD-1) | Pembrolizumab plus EP versus Placebo plus EP | 446 | 43 | No | III | Extensive-stage SCLC |
| 52 | Shitara K, et al. 2020A [80] | NCT02494583 (KEYNOTE-062) | Pembrolizumab (PD-1) | Pembrolizumab versus Pembrolizumab plus Chemotherapy (Cisplatin plus Fluorouracil/Capecitabine) | 748 | 43 | No | III | Advanced GC |
| Shitara K, et al. 2020B [80] | Pembrolizumab versus Chemotherapy | 26 |
| Shitara K, et al. 2020C [80] | Pembrolizumab plus Chemotherapy versus Chemotherapy | 37 |
| 53 | Ribas A, et al. 2020A [81] | NCT02027961 | Durvalumab (PD-L1) | Durvalumab plus Dabrafenib plus Trametinib versus Durvalumab plus Trametinib (concurrent) | 68 | 16 | Yes | I | Advanced melanoma |
| Ribas A, et al. 2020B [81] | Durvalumab plus Dabrafenib plus Trametinib versus Durvalumab plus Trametinib (sequential) | 20 |
| Ribas A, et al. 2020C [81] | Durvalumab plus Trametinib (concurrent) versus Durvalumab plus Trametinib (sequential) | 18 |
| 54 | Winer EP, et al. 2021 [82] | NCT02555657 (KEYNOTE-119) | Pembrolizumab (PD-1) | Pembrolizumab versus Single-drug Chemotherapy | 601 | 8 | Yes | III | Metastatic TNBC |
| 55 | Lee NY, et al. 2021 [83] | NCT02952586 | Avelumab (PD-L1) | Avelumab plus Chemoradiotherapy versus placebo plus Chemoradiotherapy | 692 | 56 | No | III | Locally advanced HNSCC |
| 56 | Miles D, et al. 2021 [84] | NCT03125902 (IMpassion131) | Atezolizumab (PD-L1) | Atezolizumab plus Paclitaxel versus Placebo plus Paclitaxel | 649 | 207 | No | III | Locally advanced/metastatic TNBC |
| 57 | Ren Z, et al. 2021 [85] | NCT03794440 (ORIENT-32) | Sintilimab (PD-1) | Sintilimab plus Bevacizumab biosimilar (IBI305) versus sorafenib | 565 | 49 | No | II-III | Unresectable hepatocellular carcinoma |
| 58 | Powles T, et al. 2021A [86] | NCT02853305 (KEYNOTE-361) | Pembrolizumab (PD-1) | Pembrolizumab versus Chemotherapy | 993 | 64 | No | III | Advanced UC |
| Powles T, et al. 2021B [86] | Pembrolizumab plus Chemotherapy versus Chemotherapy | 107 |
| Powles T, et al. 2021C [86] | Pembrolizumab versus Pembrolizumab plus Chemotherapy | 123 |
| 59 | Bajorin DF, et al. 2021 [87] | NCT02632409 (CheckMate 274) | Nivolumab (PD-1) | Nivolumab (Adjuvant) versus placebo | 699 | 72 | Yes | III | Muscle-invasive UC |
| 60 | Brufsky A, et al. 2021A [88] | NCT02322814 (COLET) | Atezolizumab (PD-L1) | Cobimetinib plus atezolizumab plus paclitaxel versus Cobimetinib plus paclitaxel | 152 | 32 | No | II | Advanced or metastatic TNBC |
| Brufsky A, et al. 2021B [88] | Cobimetinib plus atezolizumab plus paclitaxel versus Cobimetinib plus atezolizumab plus Nab-paclitaxel | | 28 |
| Brufsky A, et al. 2021C [88] | Cobimetinib plus paclitaxel versus Placebo plus paclitaxel | | 25 |
| 61 | Motzer R, et al. 2021A [89] | NCT02811861 (CLEAR) | Pembrolizumab (PD-1) | Lenvatinib plus Pembrolizumab versus Sunitinib | 1047 | 143 | No | III | Advanced RCC |
| Motzer R, et al. 2021B [89] | Lenvatinib plus Pembrolizumab versus Lenvatinib plus Everolimus | 184 |
| Motzer R, et al. 2021C [89] | Lenvatinib plus Everolimus versus Sunitinib | 135 |
| 62 | Bellmunt J, et al. 2021 [90] | NCT02450331 (IMvigor010) | Atezolizumab (PD-L1) | Atezolizumab versus Observation | 787 | 101 | No | III | Muscle-invasive UC |
| 63 | Choueiri TK, et al. 2021 [91] | NCT03141177 (CheckMate 9ER) | Nivolumab (PD-1) | Nivolumab plus Cabozantinib versus Sunitinib | 640 | 95 | No | III | Advanced RCC |
| 64 | Sezer A, et al. 2021 [92] | NCT03088540 (EMPOWER-Lung 1) | Cemiplimab (PD-1) | Cemiplimab versus Chemotherapy (platinum-doublet) | 697 | 26 | No | III | Advanced NSCLC |
| 65 | Paz-Ares L, et al. 2021 [93] | NCT03215706 (CheckMate 9LA) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab plus Chemotherapy versus Chemotherapy | 707 | 78 | No | III | Stage IV or recurrent NSCLC |
| 66 | Baas P, et al. 2021 [94] | NCT02899299 (CheckMate 743) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Chemotherapy | 584 | 58 | No | III | Unresectable malignant pleural mesothelioma |
| 67 | Goldman JW, et al. 2021A [95] | NCT03043872 (CASPIAN) | Durvalumab (PD-L1) | Durvalumab plus EP versus EP | 797 | 26 | No | III | Extensive-stage SCLC |
| Goldman JW, et al. 2021B [95] | Durvalumab plus Tremelimumab (CTLA-4) plus EP versus EP | 46 |
| Goldman JW, et al. 2021C [95] | Durvalumab plus Tremelimumab (CTLA-4) plus EP versus Durvalumab plus EP | 52 |
| 68 | Pujade-Lauraine E, et al. 2021A [96] | NCT02580058 (JAVELIN Ovarian 200) | Avelumab (PD-L1) | Avelumab plus PLD (Pegylated Liposomal Doxorubicin) versus PLD | 546 | 61 | Yes | III | Platinum-resistant or platinum-refractory OC |
| Pujade-Lauraine E, et al. 2021B [96] | Avelumab plus PLD versus Avelumab | 54 |
| Pujade-Lauraine E, et al. 2021C [96] | Avelumab versus PLD | 25 |
| 69 | Kelly RJ, et al. 2021 [97] | NCT02743494 (CheckMate 577) | Nivolumab (PD-1) | Nivolumab versus Placebo | 792 | 62 | Yes | III | Resected esophageal or GJC |
| 70 | Sugawara S, et al. 2021 [98] | NCT03117049 (ONO-4538-52/TASUKI-5) | Nivolumab (PD-1) | Nivolumab versus Placebo | 548 | 121 | No | III | Stage IIIB/IV or recurrent nonsquamous NSCLC |
| 71 | Yang Y, et al. 2021 [99] | NCT03707509 (CAPTAIN-1st) | Camrelizumab (PD-1) | Camrelizumab plus Gemcitabine plus Cisplatin versus Gemcitabine plus Cisplatin | 263 | 72 | No | III | NC |
| 72 | Liu SV, et al. 2021 [100] | NCT02763579 (IMpower133) | Atezolizumab (PD-L1) | Atezolizumab plus CP/ET versus Placebo plus CP/ET | 394 | 61 | No | I/III | Extensive-stage SCLC |
| 73 | Monk BJ, et al. 2021A [101] | NCT02718417 (JAVELIN Ovarian 100) | Avelumab (PD-L1) | Avelumab plus Chemotherapy + Avelumab (maintenance) versus Chemotherapy | 991 | 91 | No | III | Stage III–IV epithelial OC |
| Monk BJ, et al. 2021B [101] | Avelumab plus Chemotherapy plus Avelumab (maintenance) versus Chemotherapy plus Avelumab (maintenance) | 125 |
| Monk BJ, et al. 2021C [101] | Chemotherapy plus Avelumab (maintenance) versus Chemotherapy | 84 |
| 74 | Choueiri TK, et al. 2021 [102] | NCT03142334 (KEYNOTE-564) | Pembrolizumab (PD-1) | Pembrolizumab versus Placebo | 984 | 151 | No | III | Clear-cell, advanced RCC |
| 75 | Moore KN, et al. 2021 [103] | (NCT03038100) (IMagyn050/GOG 3015/ENGOT-OV39) | Atezolizumab (PD-L1) | Atezolizumab plus CP plus Bevacizumab versus Placebo plus CP plus Bevacizumab | 1285 | 252 | No | III | Stage III or IV OC |
| 76 | Gogas H, et al. 2021 [104] | NCT03273153 (IMspire170) | Atezolizumab (PD-L1) | Cobimetinib plus Atezolizumab versus Pembrolizumab | 436 | 118 | No | III | BRAFV600 wild-type melanoma |
| 77 | Owonikoko TK, et al. 2021A [105] | NCT02538666 (CheckMate 451) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Nivolumab | 830 | 82 | Yes | III | Extensive-disease SCLC |
| Owonikoko TK, et al. 2021B [105] | Nivolumab plus Ipilimumab versus Placebo | 76 |
| Owonikoko TK, et al. 2021C [105] | Nivolumab versus Placebo | 28 |
| 78 | Luo H, et al. 2021 [106] | NCT03691090 ((ESCORT-1st) | Camrelizumab (PD-1) | Camrelizumab plus Chemotherapy versus Chemotherapy | 595 | 22 | No | III | Advanced or metastatic ESCC |
| 79 | Colombo N, et al. 2021A [107] | NCT03635567 (KEYNOTE-826) | Pembrolizumab (PD-1) | Pembrolizumab plus Chemotherapy plus Bevacizumab versus Chemotherapy plus Bevacizumab | 389 | 65 | No | III | Persistent, recurrent, or metastatic cervical cancer |
| Colombo N, et al. 2021B [107] | Pembrolizumab plus Chemotherapy versus Chemotherapy | 227 | 17 |
| 80 | Fennell DA, et al. 2021 [108] | NCT03063450 (CONFIRM) | Nivolumab (PD-1) | Nivolumab versus Placebo | 332 | 1 | Yes | III | Malignant mesothelioma |
| 81 | Pusztai L, et al. 2021 [109] | (NCT01042379) (I-SPY2) | Durvalumab (PD-L1) | Durvalumab plus Olaparib plus Paclitaxel (DOP) versus Paclitaxel | 372 | 63 | No | II | HER2-negative stage II/III breast cancer |
| 82 | Zhu X, et al. 2021 [110] | NCT02704156 | Pembrolizumab (PD-1) | SBRT plus Pembrolizumab plus Trametinib versus SBRT plus Gemcitabine | 170 | 22 | Yes | II | Locally recurrent pancreatic cancer after surgical resection |
| 83 | Sun JM, et al. 2021 [111] | NCT03189719 (KEYNOTE-590) | Pembrolizumab (PD-1) | Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy | 740 | 47 | No | III | Advanced esophageal cancer |
| 84 | Mai HQ, et al. 2021 [112] | NCT03581786 | Toripalimab (PD-1) | Toripalimab plus GP versus Placebo plus GP | 289 | 71 | No | III | Advanced NC |
| 85 | Felip E, et al. 2021 [113] | NCT02486718 (IMpower010) | Atezolizumab (PD-L1) | Atezolizumab versus BSC | 990 | 102 | Yes | III | Resected stage IB–IIIA NSCLC |
| 86 | Larkin J, et al. 2019A [114] | NCT01844505 (CheckMate 067) | Nivolumab (PD-1) | Nivolumab plus Ipilimumab versus Nivolumab | 937 | 167 | No | III | Advanced melanoma |
| Larkin J, et al. 2019B [114] | Nivolumab plus Ipilimumab versus Ipilimumab | 162 |
| Larkin J, et al. 2019C [114] | Nivolumab versus Ipilimumab | 143 |
| Wolchok JD, et al. 2017A [115] | Nivolumab plus Ipilimumab versus Nivolumab | 165 |
| Wolchok JD, et al. 2017B [115] | Nivolumab plus Ipilimumab versus Ipilimumab | 161 |
| Wolchok JD, et al. 2017C [115] | Nivolumab versus Ipilimumab | 140 |
| Hodi FS, et al. 2018A [116] | Nivolumab plus Ipilimumab versus Nivolumab | 167 |
| Hodi FS, et al. 2018B [116] | Nivolumab plus Ipilimumab versus Ipilimumab | 162 |
| Hodi FS, et al. 2018C [116] | Nivolumab versus Ipilimumab | 143 |
| Larkin J, et al. 2015A [117] | Nivolumab versus Nivolumab plus Ipilimumab | 207 |
| Larkin J, et al. 2015B [117] | Nivolumab versus Ipilimumab | 183 |
| Larkin J, et al. 2015C [117] | Nivolumab plus Ipilimumab versus Ipilimumab | 228 |
|
